FindTrial
Sign In

Efficacy and Safety of Colchicine Anti-inflammatory Therapy in Delaying the Progression of Chronic Kidney Disease:A Real-Word Study

Efficacy and Safety of Colchicine Anti-inflammatory Therapy in Delaying the Progression of Chronic Kidney Disease:A Real-Word Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120783
Enrollment
Unknown
Registered
2026-03-19
Start date
2026-03-20
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Interventions

Colchicine-exposed group:None
Non-colchicine-exposed group (Control group):None

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old; 2. Meeting the diagnostic criteria for Chronic Kidney Disease (CKD) stages 1–5 (Estimated Glomerular Filtration Rate (eGFR) = 6 months, with complete baseline and follow-up eGFR data; 5. Complete clinical data, including demographic characteristics, medical history, laboratory tests, medication history, etc.

Exclusion criteria

Exclusion criteria: 1. Age 20%.

Design outcomes

Primary

MeasureTime frame
Annual rate of eGFR decline in patients with chronic kidney disease;—

Secondary

MeasureTime frame
Incidence of composite endpoint: eGFR decline >=30% or progression to ESRD;Incidence of adverse events (such as gastrointestinal reactions, abnormal liver enzymes, etc.);—

Countries

China

Contacts

Public ContactHuang Xiaoyan

Peking University Shenzhen Hospital

huangxiaoyan@pku.org.cn+86 135 1078 2802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026